| scholarly article | Q13442814 |
| P50 | author | Alvaro Pascual | Q60594097 |
| Mercedes Delgado-Valverde | Q98951339 | ||
| Jesús Sojo-Dorado | Q114311105 | ||
| Jesús Rodríguez-Baño | Q39065635 | ||
| P2860 | cites work | Extended-spectrum beta-lactamases: a clinical update | Q24534999 |
| Updated functional classification of beta-lactamases | Q24644798 | ||
| A functional classification scheme for beta-lactamases and its correlation with molecular structure | Q24677460 | ||
| Meta-analysis of a possible signal of increased mortality associated with cefepime use. | Q40353972 | ||
| Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate | Q40622081 | ||
| Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae | Q41870610 | ||
| Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types | Q41919138 | ||
| First detection of a carbapenem-hydrolyzing metalloenzyme in two enterobacteriaceae isolates in Spain | Q41966629 | ||
| In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models | Q42111078 | ||
| Plasmid-mediated 16S rRNA methylases in aminoglycoside-resistant Enterobacteriaceae isolates in Shanghai, China | Q42111823 | ||
| Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America | Q42111977 | ||
| In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria | Q42186280 | ||
| Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae | Q42189850 | ||
| Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized stud | Q42286867 | ||
| Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae | Q42413051 | ||
| In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases | Q42577530 | ||
| Interpretive reading of enterobacteria antibiograms | Q43004969 | ||
| Effectiveness and safety of colistin: prospective comparative cohort study | Q43124623 | ||
| Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline | Q43243711 | ||
| Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). | Q43260620 | ||
| Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase | Q43278319 | ||
| Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation | Q43289024 | ||
| Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain | Q43554150 | ||
| Clinical significance of infections caused by plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamase-producing Escherichia coli | Q44171558 | ||
| Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. | Q44219139 | ||
| Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion | Q44551301 | ||
| The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children's hospitals in China | Q44616578 | ||
| Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin | Q44709393 | ||
| Domain-domain interactions in the aminoglycoside antibiotic resistance enzyme AAC(6')-APH(2''). | Q44993651 | ||
| Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase | Q45108085 | ||
| Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. | Q45236129 | ||
| Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters | Q45341557 | ||
| Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapen | Q45915639 | ||
| Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. | Q45982863 | ||
| MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates | Q46205888 | ||
| What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression | Q26999921 | ||
| Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis | Q27002495 | ||
| Efficacy and safety of cefepime: a systematic review and meta-analysis | Q28298744 | ||
| The CTX-M beta-lactamase pandemic. | Q30356558 | ||
| Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study | Q31102336 | ||
| Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials | Q33287379 | ||
| Susceptibility of urinary tract bacteria to fosfomycin | Q33494283 | ||
| Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. | Q33500507 | ||
| Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome | Q33803393 | ||
| Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study | Q33909443 | ||
| Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009) | Q33933879 | ||
| Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase | Q33938172 | ||
| Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. | Q33945413 | ||
| Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. | Q33972587 | ||
| Mechanisms of action and resistance of older and newer fluoroquinolones | Q34030757 | ||
| Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. | Q34096605 | ||
| Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome | Q34106854 | ||
| Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers | Q34108669 | ||
| Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection | Q34109281 | ||
| Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac3-Ib/aac6'-Ib' gene cassettes in Pseudomonas aeruginosa | Q34113541 | ||
| Synthesis and spectrum of the neoglycoside ACHN-490 | Q34134992 | ||
| In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae | Q34151164 | ||
| Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes | Q34164594 | ||
| Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation | Q34188814 | ||
| The structure of β-lactamases | Q34246186 | ||
| Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions | Q34298437 | ||
| In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. | Q34301565 | ||
| Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae | Q34483491 | ||
| Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates | Q34625178 | ||
| 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides | Q34635355 | ||
| Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. | Q34726682 | ||
| Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies | Q34803735 | ||
| Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae | Q35005216 | ||
| Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae | Q35005872 | ||
| In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae | Q35065798 | ||
| Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. | Q35107937 | ||
| Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation | Q35165835 | ||
| Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. | Q35666444 | ||
| Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment | Q35840852 | ||
| Global spread of Carbapenemase-producing Enterobacteriaceae | Q35847641 | ||
| Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. | Q35867313 | ||
| Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States | Q35867321 | ||
| Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens | Q35867414 | ||
| Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli | Q35879095 | ||
| High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. | Q35977417 | ||
| New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate | Q36094929 | ||
| Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections | Q36095874 | ||
| Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece | Q36107990 | ||
| Excess deaths associated with tigecycline after approval based on noninferiority trials | Q36115632 | ||
| Mechanisms of resistance to quinolones | Q36155441 | ||
| Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions | Q36361921 | ||
| Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli. | Q36364145 | ||
| Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. | Q36482765 | ||
| Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units | Q36593857 | ||
| Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study | Q36880729 | ||
| Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations | Q37043632 | ||
| Strategies for managing today's infections | Q37101722 | ||
| Polymyxins revisited | Q37215935 | ||
| Clinical significance of extended-spectrum beta-lactamases. | Q37291354 | ||
| Ertapenem resistance of Escherichia coli | Q37302659 | ||
| AmpC beta-lactamases | Q37366249 | ||
| ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates | Q37392705 | ||
| Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem | Q37392989 | ||
| The bifunctional enzymes of antibiotic resistance | Q37555216 | ||
| Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae | Q37568924 | ||
| Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens | Q46337932 | ||
| Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. | Q46344565 | ||
| Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam | Q46431263 | ||
| In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase | Q46435439 | ||
| Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia | Q46562003 | ||
| Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. | Q46702971 | ||
| Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance | Q46711065 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. | Q46902034 | ||
| High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. | Q46929782 | ||
| Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? | Q46965068 | ||
| Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England | Q46986593 | ||
| Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England | Q47588212 | ||
| β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. | Q50523195 | ||
| Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan. | Q50932764 | ||
| Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009). | Q50948247 | ||
| Resistance in gram-negative bacteria: Enterobacteriaceae. | Q51187082 | ||
| Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator‐Associated Pneumonia: A Matched Case‐Control Study | Q51746969 | ||
| Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. | Q53138957 | ||
| Quinolone resistance from a transferable plasmid. | Q54143628 | ||
| Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. | Q54337305 | ||
| Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. | Q54347206 | ||
| Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. | Q54349462 | ||
| Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. | Q54351100 | ||
| Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. | Q54354869 | ||
| Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. | Q54361716 | ||
| Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. | Q54367445 | ||
| Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. | Q54372089 | ||
| Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. | Q54394101 | ||
| Broad-spectrum beta-lactams for treating experimental peritonitis in mice due to Escherichia coli producing plasmid-encoded cephalosporinases. | Q54434928 | ||
| Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. | Q54437371 | ||
| Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. | Q54452950 | ||
| Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. | Q54457021 | ||
| Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. | Q55054714 | ||
| Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing organisms in an intensive care unit | Q61718768 | ||
| Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy | Q64131374 | ||
| Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy | Q67973601 | ||
| Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study | Q80149746 | ||
| Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates | Q80258308 | ||
| Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital | Q80633172 | ||
| Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes | Q82043429 | ||
| Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010 | Q84502640 | ||
| Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART | Q84521838 | ||
| Risk factors for KPC-producing Klebsiella pneumoniae bacteremia | Q84974817 | ||
| Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices | Q37694529 | ||
| The future of aminoglycosides: the end or renaissance? | Q37732085 | ||
| Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials | Q37768581 | ||
| Pharmacokinetic evaluation of colistin sodium | Q37815508 | ||
| Status report on carbapenemases: challenges and prospects | Q37879199 | ||
| Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? | Q37884104 | ||
| Country-to-country transfer of patients and the risk of multi-resistant bacterial infection | Q37886438 | ||
| Efficacy and safety of tigecycline: a systematic review and meta-analysis | Q37891606 | ||
| Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes | Q37894694 | ||
| Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis | Q37904495 | ||
| New Delhi metallo-β-lactamase (NDM-1): an update. | Q37946596 | ||
| Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. | Q37952028 | ||
| EUCAST expert rules in antimicrobial susceptibility testing | Q37960940 | ||
| Antibiotics in development targeting protein synthesis | Q37970724 | ||
| Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis | Q37991287 | ||
| Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe | Q38002952 | ||
| The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae | Q38017141 | ||
| Improving known classes of antibiotics: an optimistic approach for the future | Q38022874 | ||
| Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? | Q38028701 | ||
| Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg? | Q38039214 | ||
| Mechanistic characterization of the bifunctional aminoglycoside-modifying enzyme AAC(3)-Ib/AAC(6')-Ib' from Pseudomonas aeruginosa | Q38302896 | ||
| Spread of OXA-48-encoding plasmid in Turkey and beyond | Q38933125 | ||
| In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae | Q39757874 | ||
| Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel | Q39861542 | ||
| Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection | Q40271482 | ||
| Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens | Q40280284 | ||
| Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection | Q40341858 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Enterobacteriaceae | Q380136 |
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | 49-69 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Therapeutic advances in infectious disease | Q26842293 |
| P1476 | title | Clinical management of infections caused by multidrug-resistant Enterobacteriaceae | |
| P478 | volume | 1 |
| Q36622815 | Antimicrobial resistance: a global multifaceted phenomenon |
| Q33597897 | Characteristics of carbapenemase-producing Klebsiella pneumoniae as a cause of neonatal infection in Shandong, China |
| Q91995101 | Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals |
| Q92054933 | Extended spectrum β-lactamase producing uropathogenic Escherichia coli and the correlation of biofilm with antibiotics resistance in Nepal |
| Q37593067 | Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial |
| Q93226328 | Non-clinical isolates as potential reservoirs of antibiotic resistance in Port Harcourt, Nigeria |
| Q36318328 | Phenotypic and molecular characterization of antimicrobial resistance in Enterobacter spp. isolates from companion animals in Japan |
| Q47313113 | Population Pharmacokinetics of Polymyxin B. |
| Q60934254 | Post-appendectomy pelvic abscess with extended-spectrum beta-lactamase producing : A case report and review of literature |
| Q37206036 | Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report. |
| Q47427370 | The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections |
| Q52695014 | Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. |
| Q64089906 | Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program |
Search more.